AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20868279
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation (DE) nevirapine
Trial: 17119047
Drug: Nurse-administered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered intervention consisting of cognitive behavioral therapy and medications
Trial: 17119047
Drug: Nurse-administered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered intervention and Usual care
Trial: 14624421
Drug: Acetylcysteine 600
RxNorm normalized name: acetylcysteine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine 600 mg b.i.d. (five doses)
Trial: 7699420
Drug: 'eight‐drugs‐in‐one‐day' chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'eight‐drugs‐in‐one‐day' chemotherapy regimen
Trial: 2954253
Drug: Pirprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirprofen (1200 mg daily)
Trial: 2954253
Drug: Pirprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirprofen (800 mg daily)
Trial: 2954253
Drug: Naproxen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (1000 mg)
Trial: 27697758
Drug: Tafenoquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine (300 mg) plus dihydroartemisinin-piperaquine (120 mg/960 mg for 36 to <75 kg; 160 mg/1,280 mg for ≥75 to 100 kg)
Trial: 27697758
Drug: Tafenoquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine (300 mg) plus artemether-lumefantrine (80 mg/480 mg)
Trial: 24241095
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (oral capsule, 3 g/d)
Trial: 21146844
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (liquid diet on postoperative day 2, soft diet from day 3 until discharge)
Trial: 10881255
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (oral Premarin 0.625 mg daily)
Trial: 7604069
Drug: Theophylline effervescent
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline effervescent tablet (Euphyllin quick 200)
Trial: 25876740
Drug: CR+G (genetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR+G (genetic test results and counseling)
Trial: 16912619
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg PO betamethasone
Trial: 16912619
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg IM dexamethasone
Trial: 8070785
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids infusion
Trial: 8070785
Drug: Intra-amniotic amino
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic amino acids infusion
Trial: 31592728
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with anticoagulation alone
Trial: 31592728
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for femoral-popliteal DVT
Trial: 28624307
Drug: HBVaxPro challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBVaxPro challenge dose
Trial: 26241077
Drug: Low-tidal volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-tidal volume ventilation (6 ml/kg predicted body weight)
Trial: 26241077
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care ventilation (10 ml/kg)
Trial: 17493498
Drug: Experimental medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental medications
Trial: 19803539
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 IV infusion every 21 days
Trial: 19803539
Drug: Pac3w (Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pac3w (Paclitaxel 175 mg/m2 IV infusion every 21 days)
Trial: 19803539
Drug: Pac1w (Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pac1w (Paclitaxel administered in 1-week cycles)
Trial: 10981242
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g every eight hours
Trial: 10981242
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g every eight hours
Trial: 6419574
Drug: Oral sustained-release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained-release nitroglycerin (SRNG, 6.5 mg)
Trial: 30615058
Drug: Higher triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher triglycerides (TG) ≥150 mg/dl
Trial: 30615058
Drug: Lower total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower total cholesterol (TC) ≥200 mg/dl
Trial: 30615058
Drug: Lower low-density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dl
Trial: 21410100
Drug: Functional pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional pain control infusion pump
Trial: 21410100
Drug: Placebo pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pain control infusion pump
Trial: 15581425
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg b.d. for 7 days or until discharge
Trial: 3498392
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg X kg‐1 propofol
Trial: 3498392
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg X kg‐1 ketamine
Trial: 22780582
Drug: 7.5% CO₂
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% CO₂ inhalation
Trial: 9451886
Drug: MIBI bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIBI bone scans post-chemotherapy
Trial: 8179134
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg human corticotropin releasing hormone
Trial: 8179134
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg human corticotropin releasing hormone
Trial: 8179134
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no human corticotropin releasing hormone)
Trial: 3332509
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Trial: 3332509
Drug: 3 tablets
RxNorm normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Trial: 21145578
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg dose of 2009 H1N1 vaccine
Trial: 21145578
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg dose of 2009 H1N1 vaccine
Trial: 21145578
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Trial: 21145578
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Trial: 21145578
Drug: Both 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 15 μg and 30 μg doses of 2009 H1N1 vaccine
Trial: 22802432
Drug: 2009 H1N1
RxNorm normalized name: influenza A virus A/California/7/2009 (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 H1N1 vaccine
Trial: 11687731
Drug: ACE-inhibitor trandolapril
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor trandolapril (4 mg)
Trial: 11687731
Drug: Non-dihydropyridinic Ca2+
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-dihydropyridinic Ca2+ channel blocker verapamil (240 mg)
Trial: 11687731
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trandolapril (2 mg) and verapamil (180 mg)
Trial: 12959316
Drug: Racemic tranylcypromine
RxNorm normalized name: Racemic Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic tranylcypromine (20 mg of the sulphate)
Trial: 12959316
Drug: Single enantiomers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single enantiomers of tranylcypromine (10 mg of the sulphate)
Trial: 18079431
Drug: Perioperative parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Perioperative parecoxib 40 mg
Trial: 18079431
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative parecoxib dose
Trial: 12584282
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa at doses of 0.45 and 0.75 microg/kg/week
Trial: 11041909
Drug: Rofecoxib (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (12.5, 25, or 50 mg combined)
Trial: 11041909
Drug: NSAIDs (ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ibuprofen, diclofenac, or nabumetone combined)
Trial: 1377305
Drug: Nitrendipine (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (morning dosage) 20 mg
Trial: 1377305
Drug: Nitrendipine (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (evening dosage) 20 mg
Trial: 9389278
Drug: Pethidine 25
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 25 mg
Trial: 22577906
Drug: Morphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2.5 mg
Trial: 31183923
Drug: Prostate-specific antigen
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-specific antigen screening and digital rectal examination
Trial: 29486797
Drug: BTH1677 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTH1677 (4 mg/kg IV weekly) + bevacizumab (15 mg/kg IV Q3W) + carboplatin (6 mg/mL/min Calvert formula Q3W) + paclitaxel (200 mg/m2 Q3W)
Trial: 21316934
Drug: Phytosterol supplementation
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol supplementation (4 g per day via 2 plant sterol-enriched yogurt mini drinks)
Trial: 7484282
Drug: Calcium tablets
RxNorm normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium tablets 1 g/night
Trial: 7484282
Drug: Milk powder
RxNorm normalized name: Milk powder
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder containing 1 g of calcium
Trial: 7484282
Drug: Calcium tablets
RxNorm normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium tablets 1 g/night and exercise regimen
Trial: 2301454
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined drug therapy (propranolol and chlorthalidone) with an educational program on hypertension, dietary and exercise modification.
Trial: 7783014
Drug: Implant overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant overdentures
Trial: 24972949
Drug: Traditional trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional trivalent split virion vaccine (TIIV)
Trial: 24972949
Drug: Virosome-adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV)
Trial: 22653877
Drug: L‐AMT
RxNorm normalized name: Levomethamphetamine
DrugBank: Levmetamfetamine (DB09571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L‐AMT
Trial: 22653877
Drug: L/D‐AMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/D‐AMT
Trial: 30033159
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg caffeine
Trial: 8169187
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg caffeine
Trial: 17227904
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.)
Trial: 17227904
Drug: Oral cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide, thalidomide, and prednisone (CTP)
Trial: 7657279
Drug: No albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No albumin infusion (Control)
Trial: 2663695
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human alpha-interferon-2a, 9 million units intramuscularly three times weekly for 16 weeks, followed by 3 million units three times weekly for an additional 8 weeks if viremic after 16 weeks.
Trial: 1151628
Drug: Elixir, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elixir, 0.5 mg digoxin
Trial: 1151628
Drug: Rapid dissolution
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid dissolution tablet, 0.5 mg digoxin
Trial: 1151628
Drug: Slow dissolution
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow dissolution tablet, 0.5 mg digoxin
Trial: 1151628
Drug: Intravenous administration,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration, 0.5 mg digoxin
Trial: 26437761
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium nitrate (NO donor)
Trial: 24521888
Drug: Furazolidone-based quadruple
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone-based quadruple therapy (Esomeprazole 20 mg twice daily, furazolidone 100 mg twice daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Trial: 24521888
Drug: Levofloxacin-based quadruple
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based quadruple therapy (Esomeprazole 20 mg twice daily, levofloxacin 500 mg daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Trial: 21248158
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of HPV vaccine (Gardasil) for group 1, months 0 and 6
Trial: 21248158
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of HPV vaccine (Gardasil) for group 2, months 0, 2, and 6
Trial: 21248158
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of HPV vaccine (Gardasil) for group 3, months 0, 2, and 6
Trial: 18081355
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 400 microg buccally
Trial: 18081355
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 400 microg sublingually
Trial: 16448525
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 or 15 mg continuously for 12 months
Trial: 14567773
Drug: Raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCl 60 mg daily
Trial: 11375775
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) delivered intermittently at low doses
Trial: 9758073
Drug: Integrated psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated psychological treatment program (self-help techniques, cognitive behavioral strategies, relaxation, physical exercises)
Trial: 9758073
Drug: Integrated psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated psychological treatment program
Trial: 8076546
Drug: Intranasal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxygen supplementation
Trial: 3396490
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (controls)
Trial: 26548726
Drug: AverTeaX applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AverTeaX applied topically six to eight times daily
Trial: 22976217
Drug: Betaine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (1.25 g BID)
Trial: 18031471
Drug: Mirtazapine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30 mg daily)
Trial: 17013640
Drug: Priming drink
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming drink (0.03 g/dl alcohol)
Trial: 11258039
Drug: Onion-olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion-olive oil maceration product (4 capsules daily)
Trial: 11258039
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules daily)
Trial: 29266863
Drug: Nebulized hypertonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized hypertonic saline (3% HS) with 2.5 mg salbutamol
Trial: 29266863
Drug: Nebulized normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized normal saline (NS) with 2.5 mg salbutamol
Trial: 27439433
Drug: Metformin 2
RxNorm normalized name: metformin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2 g (1 g twice daily) plus lifestyle
Trial: 22427815
Drug: SVM3 model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVM3 model constructed by combination of SVM1 and SVM2
Trial: 19625372
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention targeting LDL-cholesterol <100 mg/dl, using antiplatelet therapy, and switching protease inhibitor therapy.
Trial: 19625372
Drug: Standard intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intervention aiming for LDL-cholesterol <130 mg/dL.
Trial: 14993579
Drug: Buffered lidocaine
RxNorm normalized name: buffered lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered lidocaine (0.1 to 0.2 mL subcutaneously injected just before PIV insertion)
Trial: 7837398
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg orally
Trial: 7837398
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg orally
Trial: 7837398
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intramuscularly
Trial: 17191188
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis)
Trial: 17191188
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PDT and intravitreal triamcinolone acetonide
Trial: 11398072
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg of IL‐4R
Trial: 9291263
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture supported by two implants with ball attachments
Trial: 9291263
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants with an interconnecting bar
Trial: 9291263
Drug: Four interconnected
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four interconnected implants
Trial: 28612375
Drug: ABVE chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVE chemotherapy and 25.5 Gy of involved field radiotherapy for low-risk HL (P9426)
Trial: 28612375
Drug: ABVE-PC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVE-PC chemotherapy and 21 Gy of involved region radiotherapy for intermediate and high-risk HL (P9425)
Trial: 25434365
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg) administered 30 min prior to surgery and every 12 h for 60 h